Joined November 2019
- Tweets 68
- Following 63
- Followers 192
- Likes 51
28 Photos and videos
15 Jun 2024
Thanks to "DM Arena" for organizing the Post ASCO meeting this week. It was a pleasure to contribute.
dagensmedisin.no/dmarena/dm-…
@DagensMedisin @dagensmedicin @Oslounivsykehus @fkbmatrix @OsloCancer
1
86
15 Jun 2024
Congratulations to @KjetilTasken for receiving the Annual Excellent Researcher Award from @Oslounivsykehus today – well deserved!
4
92
13 May 2024
Thrilled to announce our paper "Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform" has been chosen as an Editor’s Choice Article for 2022-2023!
Thanks to our dedicated team and contributors.
9 May 2024
📣 Check out Editor’s Choice Articles from 2022–2023 Related to Methods and Technologies Development
🤗 Find more details here: mdpi.com/journal/cancers/ann…
1
94
24 Apr 2024
Delighted to share that our article "Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation" has been published npj Breast Cancer
nature.com/articles/s41523-0…
1
5
120
Kyte Group retweeted
3 Apr 2024
Vi gratulerer Johanna Olweus & The Matchmakers som er en av fem vinnere av Cancer Grand Challenges og får 250 millioner til å løse en av de store utfordringene unnen kreftforskning instagram.com/reel/C5QKl28h4…
2
3
74
13 Feb 2024
On February 9th, Andreas Hagen Røssevold triumphantly completed his Ph.D. defense on "Immunotherapy and immunological biomarkers in breast cancer" at the OUH. For more details on his groundbreaking research, read his recent publications on @NatureMedicine and @jitcancer.
1
4
115
Kyte Group retweeted
9 Feb 2024
Congratulations to Andreas Røssevold MD, PhD with his fantastic PhD defence and discussion over the outcomes of the Alice snd Icon trials @GroupKyte @UniOslo_MED @RESCUER2020
1
6
298
25 Jan 2024
Excited to announce our pioneer ICON clinical trial study published in @jitcancer. Thanks to our patients, collaborators, and funders (BMS, Health Region South East, Pink Ribbon/Norwegian Cancer Society). #MATRIX #Oncodistinct #JulesBordet jitc.bmj.com/content/12/1/e0…
2
10
162
1 Dec 2023
🔬 Exciting Postdoc Opportunity
🔍 Join us in advancing Machine Learning for Cancer Immunotherapy.
We're looking for a talented Postdoctoral Researcher to join our team.
Explore the details and apply here:
2411.webcruiter.no/Main2/Rec…
2
8
516
26 Nov 2023
Big thanks to the Norwegian Society of Immunology for honoring our ALICE article (Nat Med) with the NSI 2023 Research Prize! 🏆
Gratitude to the Norwegian Cancer Society/Pink Ribbon, Heath Region South East, Roche, ALICE team, study sites, and above all, our resilient patients.
1
12
822
20 Nov 2023
Exciting Postdoc Opportunity in CAR T cell!
🌐 We're seeking a talented researcher to join our team at the Institute for Cancer Research, Oslo University Hospital (OUH).
Explore cutting-edge innovative projects and contribute to groundbreaking research.
finn.no/job/fulltime/ad.html…
1
242
13 Nov 2023
We are honored and grateful to the Cancer Society & Pink Ribbon for awarding their Open Call grant to our project on personalised breast cancer immunotherapy - look forward to getting on with the work!
6
223
2 May 2023
Åslaug Helland fikk i dag overrakt Kong Olav´s kreftforskningspris av Kong Harald i Universitetets Aula. Gratulerer, Åslaug - vel fortjent!
@HellandAslaug
3
17
646
27 Apr 2023
Congratulations to Professor Åslaug Helland with King Olav V's Prize for Cancer Research!!
Very well deserved! We look forward to working together with Åslaug to further advance cancer research, within and beyond the new national center MATRIX.
@HellandAslaug
14
360
3 Feb 2023
We are looking for a highly motivated and skilled "Special engineer" in cancer immunotherapy.
Check out the ad if you are interested in joining a dynamic cutting-edge research group.
2411.webcruiter.no/Main2/Rec…
1
9
831
9 Dec 2022
A new method of treating aggressive breast cancer offers hope for more patients.
Norwegian researchers receive international attention for their findings.
nrk.no/osloogviken/1.1620275…
4
18
Kyte Group retweeted
8 Dec 2022
In patients with metastatic triple-negative #BreastCancer, atezolizumab anthracycline-based chemotherapy improves progression-free survival, including in PD-L1 negative disease #SABCS22 @andreashr @GroupKyte @AmundJon @Oslounivsykehus @UniOslo_MED #BCsm nature.com/articles/s41591-0…
13
30
8 Dec 2022
We are delighted to share that the first results from the ALICE-trial were today published in Nature Medicine and presented at San Antonio Breast Cancer Symposium. Thanks to the patients and the study teams. Look forward to further work.
rdcu.be/c1geA
7
30